Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACORGet Rating) in a report published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Stock Performance

Shares of ACOR opened at $0.62 on Monday. The company has a market cap of $14.98 million, a PE ratio of -0.09 and a beta of 1.64. The company has a current ratio of 1.71, a quick ratio of 1.34 and a debt-to-equity ratio of 2.48. The stock has a 50-day moving average price of $0.52 and a 200-day moving average price of $0.49. Acorda Therapeutics has a 12-month low of $0.26 and a 12-month high of $3.23.

Institutional Trading of Acorda Therapeutics

A number of large investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its holdings in shares of Acorda Therapeutics by 27.4% during the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 194,100 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Acorda Therapeutics by 661.2% during the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 270,588 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Acorda Therapeutics during the 2nd quarter valued at about $68,000. Finally, Prudential Financial Inc. purchased a new position in shares of Acorda Therapeutics during the 2nd quarter valued at about $28,000. Institutional investors own 50.24% of the company’s stock.

About Acorda Therapeutics

(Get Rating)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

Featured Stories

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.